Cargando…

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma

BACKGROUND: Standard therapy for patients with stage I-III squamous cell carcinoma (SCC) of the anal canal is chemo-radiotherapy with 5-fluorouracil (5-FU) and mitomycin C (MMC). While there is limited published evidence to substitute capecitabine (CAP) for 5-FU, the objectives of the study were to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thind, Govin, Johal, Bal, Follwell, Matthew, Kennecke, Hagen Fritz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050390/ https://www.ncbi.nlm.nih.gov/pubmed/24885554 http://dx.doi.org/10.1186/1748-717X-9-124

Ejemplares similares

Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer
por: Mineur, Laurent, et al.
Publicado: (2023)

Concurrent Chemoradiation With 5-Fluorouracil and Mitomycin in Squamous Cell Carcinoma of the Rectum
por: Sethi, Ashish K
Publicado: (2021)

Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation
por: Dricken, Julie, et al.
Publicado: (2020)

Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal
por: Saint, Angélique, et al.
Publicado: (2019)

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
por: Hofheinz, R-D, et al.
Publicado: (2004)

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
por: Ernst, T, et al.
Publicado: (2007)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

Long-Term Outcomes of Chemoradiation for Anal Cancer Patients
por: Kim, Hun Jin, et al.
Publicado: (2013)

Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy
por: Silva, Ninoska N., et al.
Publicado: (2012)

Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database
por: Bian, Shelly X., et al.
Publicado: (2020)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer
por: Hernandez, Sharia, et al.
Publicado: (2023)

Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study
por: Truelsen, Christina Glismand, et al.
Publicado: (2021)

Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis
por: Souza, Karla T, et al.
Publicado: (2016)

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
por: Northover, J, et al.
Publicado: (2010)

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma
por: Grave, Athénaïs, et al.
Publicado: (2022)

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option
por: Meulendijks, D, et al.
Publicado: (2014)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
por: Rao, S, et al.
Publicado: (2004)

Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis
por: Koerber, Stefan Alexander, et al.
Publicado: (2014)

Brachytherapy boost after chemoradiation in anal cancer: a systematic review
por: Frakulli, Rezarta, et al.
Publicado: (2018)

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study
por: Klautke, G, et al.
Publicado: (2006)

Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I‐II or unresected stage III pancreatic cancer
por: Ma, Sung J., et al.
Publicado: (2019)

Laryngeal preservation in stage III/IV resectable laryngo-hypopharyngeal squamous cell carcinoma following concurrent chemoradiotherapy with capecitabine/cisplatin
por: AHN, DONGBIN, et al.
Publicado: (2013)

A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
por: Khurshid, Humera, et al.
Publicado: (2012)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study
por: Dellas, Kathrin, et al.
Publicado: (2012)

How I treat anal squamous cell carcinoma
por: Martini, Giulia, et al.
Publicado: (2020)

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
por: Feng, Yan-Ru, et al.
Publicado: (2016)

Penile Mondor's disease in a patient treated with radical chemoradiation for anal cancer
por: Pittaka, Maria, et al.
Publicado: (2017)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma
por: Soriano, Celine, et al.
Publicado: (2022)

Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer
por: Chau, I, et al.
Publicado: (2003)

Preoperative Chemoradiation in Locally Advanced Rectal Cancer: A Comparison of Bolus 5-Fluorouracil/Leucovorin and Capecitabine
por: Yoney, Adnan, et al.
Publicado: (2014)

Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer
por: Zhu, Ji, et al.
Publicado: (2020)

A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial)
por: Murofushi, Keiko Nemoto, et al.
Publicado: (2022)

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei
por: Farquharson, A L, et al.
Publicado: (2008)

Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2)
por: Gollins, S W, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_f8enccdll3bjljf5rh818irstv